2,46 1,70 1,70 two,85 2,75 3,45 three,60 four,56 three,63 three,05 3,25 1.six 1,50 A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A B C A C A C C B C C B C C A A C AbMt A A C Mt A A C CzMt A A C Mt Single TNFiMt A A C CzMt TNFiMt A A C Mt Single 199 A C C AdMt TNFiMt 183 A C C Mt Single 172 A A C AdMt TNFiMt 267 0,7 10,9 A A C Mt Single 251 0,8 A C C InMt TNFiMt 306 0,eight A C C Mt Single 226 0,9 Sharp Sharp A C C InMt TNFiMt 71 10,0 Sharp A C C Mt Single 64 11,0 Sharp 82,0 A C C EtMt TNFiMt 246 0,7 Sharp 5,0 A C C Mt Single 230 0,eight Sharp five,0 A C C EtMt TNFiMt 218 six,8 Sharp 9,5 280 A C C Mt Single 212 six,8 Sharp 11,five 280 C C B SuMtGc Triple 70 0,3 Sharp two,0 280 C C B Su Single 65 0,3 Sharp 5,0 280 13 B A A MtSuCl Triple 97 0,six Larsen 2,0 240 24 B A A Mt Single 98 0,7 Larsen two,0 240 24 C C A MtSuCl Triple 52 1,six Sharp 28,0 280 18 C C A Su Single 47 1,7 Sharp 32,0 280 18 B C B MtSuCl Triple 58 2,two Larsen 33,4 200 24 B C B MtSu Double 56 2,5 Larsen 33,six 200 24 B C B Mt Single 57 2,three Larsen 32,eight 200 24 Yes Yes Yes Yes Yes No No No No No No No No No No Yes Yes No No Yes Yes No No No No Yes Yes Yes Yes No No YesSequence generation Incomplete Test outcome Sponsor drug Therapy group N_ (radiograph) Duration RA, Scoring years system Duration of study, monthsConRadiocealed graphic alloStudy Outcome secation blinding blinding quenceInitial radiographic scoreRadiographic score, MaxMean Dose GC mgStrategy alter allowedDMARD inadequate response No No No No No No No No No No No No No Yes Yes No No No No Yes Yes Yes Yes Yes Yes Yes Yes No No Yes Yes NoPLOS A single | plosone.org[29]BBC[29]BBC[29]BBC[30]AAC[30]AAC[31]AAC[31]AAC[32]AAA[32]AAA[33]BAA[33]BAA[34]AAA[34]AAA4 Mixture Therapy in Rheumatoid Arthritis[35]BBB[35]BBB[36]AAA[36]AAA[37]BBA[37]BBA[38]BBA[38]BBA[39]BBA[39]BBA[40]BBA[40]BBA[41]AAB[41]AAB[42]BBA[42]BBA[43]BBC[43]BBC[44]AAATable 1. Cont.Reference no. PARPR three,9 2,8 two,7 1,five 1,2 1,three 1,five two,two 12 24 24 280 280 448 NA NA NA Sharp Sharp Sharp 4 Sharp 13,three 12,four 5,1 five,4 448 448 448 448 448 280 280 six 6 11 11 11 11 12 12 six six two,2 0,0 0,0 1,three 1,three NA NA NA NA two,4 2,three 0,four 0,5 two,40 2,20 three,40 three,50 four,80 five,60 three,45 3,10 0 0 NA NA three,54 3,83 four,07 3,81 2 two,11 two,three two,05 0.BuyMethyl 5-bromo-2,4-dimethylbenzoate eight A A A B B B B B B A A A A A A A A A A A A B A C AdMt TNFiMt 508 B A C Mt Single 514 B C C OcMt CD20iMt 194 1,2 four,5 B C C Mt Single 196 1,23 A C C OcMt CD20iMt 277 12,three C C C Mt Single 282 11,8 Sharp Sharp B C C OcMt CD20iMt 324 7,six Sharp B C C Mt Single 285 7,2 Sharp NA A B C GoMt TNFiMt 81 eight,8 Sharp 32,1 A B C Mt Single 84 eight,7 Sharp 30,8 C C A MtGc Double 112 0,6 Sharp 0 280 C C A Mt Single 110 0,6 Sharp 0 280 B B C TzMt TZMt 398 9,three Sharp 29,1 145 B B C Mt Single 393 9 Sharp 28,8 145 12 B A C GoMt TNFiMt 89 4,five Sharp 29,7 448 12 B A C Mt Single 133 6,5 Sharp 36,7 448 12 B A C GoMt TNFiMt 159 three,5 Sharp 18,7 448 12 B A C Mt Single 160 two,9 Sharp 19,7 448 12 A A C RtMt CD20iMt 244 0,90 Sharp 3,50 145 12 A A C Mt Single 232 0,90 Sharp three,70 145 12 B C A MtBu Double 15 0,eight Sharp 14 448 22 Yes No No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No No No No No NoSequence generation Incomplete Test outcome Sponsor drug Treatment group N_ (radiograph) Duration RA, Scoring years method Duration of study, monthsConRadiocealed graphic alloStudy Outcome secation blinding blinding quenceInitial radiographic scoreRadiographic score, MaxMean Dose GC mgStrategy transform allowedDMARD inadequate response No No No No No Yes Yes Yes Yes No No Yes Yes Yes Yes Yes Yes No No No NoPLOS A single | plosone.2,4-Dimethyl-1H-pyrrole Order org[44]AAA[45]AAA[45]AAA[.PMID:24428212